CAS 926037-48-1

Radotinib

Description:

Radotinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of chronic myeloid leukemia (CML). It selectively targets the BCR-ABL fusion protein, which is responsible for the proliferation of cancerous cells in CML. The compound exhibits a high affinity for the ATP-binding site of the BCR-ABL kinase, effectively inhibiting its activity and leading to reduced cell proliferation and increased apoptosis of malignant cells. Radotinib is characterized by its oral bioavailability and a favorable pharmacokinetic profile, allowing for convenient administration. Its chemical structure includes a pyrimidine ring, which is common among many kinase inhibitors, contributing to its mechanism of action. The substance has undergone various clinical trials to assess its efficacy and safety, demonstrating promising results in patients with resistant forms of CML. As with many targeted therapies, potential side effects may include hematological toxicities and other adverse reactions, necessitating careful monitoring during treatment. Overall, Radotinib represents a significant advancement in the therapeutic landscape for CML.

Formula: C₂₇H₂₁F₃N₈O

InChI: InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)

InChI key: InChIKey=DUPWHXBITIZIKZ-UHFFFAOYSA-N

SMILES: C(F)(F)(F)C=1C=C(C=C(NC(=O)C2=CC(NC=3N=C(C=CN3)C=4C=NC=CN4)=C(C)C=C2)C1)N5C=NC(C)=C5

Synonyms:

• 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]benzamide
• 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide
• Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]-
• Radotinib
• Unii-I284Ljy110
• IY5511 HCl.
• Radotinib HCl
• IY5511
• Radotinib(IY-5511)
• Supect
• RADOTINIB; IY5511 HCL.

SUPECT

CAS: 926037-48-1

Formula: C₂₇H₂₁F₃N₈O

Purity: %

Color and Shape: Solid

Molecular weight: 530.5038

Ref: IN-DA00H1JD

Radotinib

CAS: 926037-48-1

Radotinib

Formula: C₂₇H₂₁F₃N₈O

Purity: ≥98%

Molecular weight: 530.5

Ref: 54-BUP10471

Radotinib-d6

CAS: 926037-48-1

Formula: C₂₇H₁₅D₆F₃N₈O

Color and Shape: Off-White Solid

Molecular weight: 536.55

Ref: 4Z-R-114002

Radotinib

CAS: 926037-48-1

Formula: C₂₇H₂₁F₃N₈O

Color and Shape: Brown Solid

Molecular weight: 530.52

Ref: 4Z-R-114001

Radotinib

CAS: 926037-48-1

Radotinib (IY-5511), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably

Formula: C₂₇H₂₁F₃N₈O

Purity: 99.13% - 99.97%

Color and Shape: Solid

Molecular weight: 530.5038

Ref: TM-T2328

Radotinib

CAS: 926037-48-1

Inhibitor of BCR-ABL1 kinase

Formula: C₂₇H₂₁F₃N₈O

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 530.5 g/mol

Ref: 3D-FR103403

Radotinib

CAS: 926037-48-1

Formula: C₂₇H₂₁F₃N₈O

Molecular weight: 530.5

Ref: BE-RMCR006000

Radotinib

CAS: 926037-48-1

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzamide

Formula: C₂₇H₂₁F₃N₈O

Purity: 98+%

Molecular weight: 530.5

Ref: IN-DG631022

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzamide

CAS: 926037-48-1

Purity: 98+%

Molecular weight: 530.515

Ref: 10-F981163